Tanaka, T., Miyamoto, Y., Sakai, A., & Fujimoto, N. (2020). Nivolumab for malignant peritoneal mesothelioma. BMJ Case Rep.
Chicago Style CitationTanaka, Takaaki, Yosuke Miyamoto, Atsue Sakai, i Nobukazu Fujimoto. "Nivolumab for Malignant Peritoneal Mesothelioma." BMJ Case Rep 2020.
Cita MLATanaka, Takaaki, Yosuke Miyamoto, Atsue Sakai, i Nobukazu Fujimoto. "Nivolumab for Malignant Peritoneal Mesothelioma." BMJ Case Rep 2020.
Atenció: Aquestes cites poden no estar 100% correctes.